DSIP vs Octreotide
Overview
DSIP is primarily a sleep & recovery peptide, while Octreotide is used for hormonal.
This page compares DSIP and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| DSIP | Octreotide | |
|---|---|---|
| Category | Sleep & Recovery | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 100-300 mcg | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | before bed | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | Improved deep sleep, stress reduction, recovery enhancement, pain reduction | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | Very well-tolerated, possible grogginess | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. DSIP is categorised under Sleep & Recovery, while Octreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. DSIP: not FDA-approved; compounding permitted with a prescription as of April 2026. Octreotide: FDA-approved.
Dosing. DSIP is typically dosed at 100-300 mcg (before bed). Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking DSIP and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between DSIP and Octreotide?
- DSIP is primarily a sleep & recovery peptide, while Octreotide is used for hormonal. DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Octreotide is FDA-approved for one or more indications.
- What is DSIP used for?
- Delta sleep-inducing peptide.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take DSIP and Octreotide together?
- Some users combine peptides within a single protocol, but stacking DSIP and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is DSIP or Octreotide FDA-approved?
- DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026). Octreotide is FDA-approved for one or more indications.
Read the full articles
- DSIP — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references